Skip to content

    Global Health Limited

    MEDANTAGood
    Healthcare·16 May 2025
    Management Summary

    Global Health (Medanta) delivered a steady FY25 performance characterized by double-digit revenue growth and strong margins in its developing units. The company is entering an aggressive growth phase, planning to double its bed capacity to ~6,000 beds via a ₹4,000 crore capex program. Management remains confident in the ramp-up of new facilities like Noida and Ranchi while maintaining healthy cash surpluses to fund expansion.

    Highlights

    8

    • FY25 Consolidated Income reached ₹37,714 million, a 13% YoY growth.

    • FY25 EBITDA stood at ₹9,562 million with a margin of 25.4%.

    • Q4 FY25 EBITDA margin expanded to 26.0% from 24.7% in the previous year.

    • Adjusted PAT for FY25 was ₹5,186 million, up 9% YoY, after excluding merger-related costs.

    • Announced a massive expansion plan to add ~3,000 beds over the next 3-4 years with a ₹4,000 crore outlay.

    • Noida facility (550 beds) is on track to become operational in Q2 FY26.

    • Board recommended the first-ever dividend of 25% (₹0.5 per share).

    • Developing hospitals (Lucknow and Patna) registered a 30% EBITDA margin for the full year.

    What Changed2

    vs Q1 FY26

    Guidance items10 → 6 (-4)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    06 metrics
    1. 01Total Income37,714 Mn+13%YoY
    2. 02EBITDA Margin25.4%
    3. 03Adjusted PAT5,186 Mn+9%YoY
    4. 04ARPOB₹62,722+1.3%YoY
    5. 05Occupancy Rate62%

    Segment breakdown

    • Mature Hospitals26,119 Mn70.5%
    • Developing Hospitals (Lucknow & Patna)10,940 Mn29.5%
    Donut· Share of Revenue

    Guidance & targets

    6
    CategoryTargetPriority
    Capacity
    Bed Additions
    1,000 beds
    		High
    Capacity
    Noida Facility Operationalization
    550 beds
    		High
    Capacity
    Ranchi O&M Hospital
    110 beds
    		High
    Capacity
    Guwahati Project Cost
    ₹500 crores
    		Medium
    Capex
    Total Expansion Outlay
    ₹4,000 crores
    		High
    Pricing
    Tariff Hikes
    Nominal/Inflation-linked
    		Medium

    Risks & concerns

    4
    RiskSeverity

    ARPOB Dilution from Payer Mix

    Increased share of PPP and government scheme patients in Patna and Lucknow has led to a 4% YoY decline in ARPOB for developing units. — Both acknowledged

    medium

    Competitive Intensity in NCR and Lucknow

    Management believes the 'rising tide lifts all boats' and that these regions are becoming medical hubs, absorbing new capacity. — Analyst downplayed

    low

    Project Execution Timelines

    Greenfield projects like Mumbai and Pitampura have long lead times (~3 years), making near-term growth dependent on existing facility ramp-ups. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific transplant volume numbers were not available off-hand during the call.

    Q&A highlights

    3

    “Yes, I said INR 4,000 crores.”

    Confirms the massive scale of investment intended to double the company's capacity, a key driver for long-term valuation.

    asked by Vinayak Mohta, Axia Asset

    2 min read5 chapters

    Detailed Narrative

    01

    Aggressive Capacity Expansion Roadmap

    Medanta is embarking on a significant expansion phase, aiming to double its current bed capacity by adding approximately 3,000 beds over the next 3 to 4 years. This growth is backed by a ₹4,000 crore capital outlay, which includes ₹450 crores for maintenance capex. Key projects include a 550-bed facility in Noida, a 500+ bed hospital in Mumbai, and a 750-bed super specialty hospital in Pitampura, Delhi.

    02

    Operational Performance of Mature vs. Developing Units

    Mature hospitals saw revenue growth of 11% in FY25, reaching ₹26,119 million with a steady 25% EBITDA margin. Developing units (Lucknow and Patna) registered 10% revenue growth to ₹10,940 million and achieved a superior EBITDA margin of 30%. However, ARPOB in developing units declined by 4% to ₹54,303, primarily due to a higher mix of PPP and government scheme patients in Patna and Lucknow.

    03

    Strategic Entry into Noida and Guwahati

    The Noida facility is a major upcoming milestone, set to operationalize 550 beds in Q2 FY26. Management highlighted that Noida has historically been underserved in terms of quality hospital beds despite a dense population. Additionally, the board approved a new 400-bed project in Guwahati with an estimated cost of ₹500 crores, aiming to serve the entire Northeastern region of India.

    04

    Financial Strength and Capital Allocation

    The company ended FY25 with a strong net cash surplus of ₹8,123 million, providing a solid foundation for its expansion plans. Total consolidated income grew 13% to ₹37,714 million, while adjusted PAT rose 9% to ₹5,186 million. Reflecting this financial health, the board recommended its first-ever dividend of 25%, amounting to ₹0.5 per share.

    05

    Clinical Milestones and Technology Investment

    Medanta continues to invest in high-end clinical capabilities, having performed over 100 robotic procedures in Lucknow within six months. The group also achieved milestones in CAR-T cell therapies and secured a patent for a brachytherapy device (MAOLO) for cervical cancer. International patient revenue grew by 8% YoY to ₹2,086 million, contributing roughly 6% of total revenue.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.